A detailed history of Bank Of America Corp transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 70,232 shares of ACET stock, worth $63,208. This represents 0.0% of its overall portfolio holdings.

Number of Shares
70,232
Previous 70,438 0.29%
Holding current value
$63,208
Previous $85,000 18.82%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.07 - $1.63 $220 - $335
-206 Reduced 0.29%
70,232 $101,000
Q2 2024

Aug 14, 2024

SELL
$1.21 - $2.4 $38,188 - $75,746
-31,561 Reduced 30.94%
70,438 $85,000
Q1 2024

May 15, 2024

BUY
$1.76 - $3.45 $95,490 - $187,183
54,256 Added 113.64%
101,999 $239,000
Q4 2023

Feb 14, 2024

BUY
$1.11 - $1.89 $15,272 - $26,004
13,759 Added 40.49%
47,743 $90,000
Q2 2023

Aug 14, 2023

SELL
$2.13 - $7.13 $9,090 - $30,430
-4,268 Reduced 11.16%
33,984 $82,000
Q1 2023

May 12, 2023

SELL
$5.52 - $9.23 $784,932 - $1.31 Million
-142,198 Reduced 78.8%
38,252 $220,000
Q4 2022

Feb 10, 2023

BUY
$7.72 - $21.27 $460,636 - $1.27 Million
59,668 Added 49.4%
180,450 $1.61 Million
Q3 2022

Nov 14, 2022

BUY
$13.43 - $18.74 $1.32 Million - $1.84 Million
98,146 Added 433.58%
120,782 $1.72 Million
Q2 2022

Aug 12, 2022

SELL
$10.26 - $20.81 $132,374 - $268,490
-12,902 Reduced 36.3%
22,636 $330,000
Q1 2022

May 16, 2022

SELL
$11.53 - $19.97 $434,911 - $753,268
-37,720 Reduced 51.49%
35,538 $710,000
Q4 2021

Feb 08, 2022

BUY
$7.37 - $17.49 $446,452 - $1.06 Million
60,577 Added 477.7%
73,258 $1.28 Million
Q3 2021

Nov 15, 2021

BUY
$6.29 - $9.93 $29,984 - $47,336
4,767 Added 60.24%
12,681 $99,000
Q2 2021

Sep 13, 2021

BUY
$9.19 - $15.93 $72,729 - $126,070
7,914 New
7,914 $82,000

Others Institutions Holding ACET

About Adicet Bio, Inc.


  • Ticker ACET
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,030,800
  • Market Cap $36M
  • Description
  • Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...
More about ACET
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.